C
Cloudbreak Therapeutics
About Cloudbreak Therapeutics
Cloudbreak Pharma, based in Irvine, California, is a clinical-stage pharmaceutical company that specializes in the research and development (R&D) of drugs for ocular diseases. Founded in September 2015, the company operates in the healthcare sector, specifically in the ophthalmic drug market. The team at Cloudbreak Pharma is diverse and has extensive experience in ocular drug R&D, which is the process of discovering, testing, and producing new drugs to treat eye diseases.
The company's business model revolves around the development of innovative treatments for various ocular diseases. These include pterygium (a growth on the eye's surface), pinguecula (a yellowish bump on the eye), meibomian gland dysfunction (a common type of dry eye disease), glaucoma filtration surgery, adjunct therapy for glaucoma filtration surgery, age-related macular degeneration (a common eye condition among people over 50), and diabetic retinopathy (a diabetes complication that affects eyes).
Cloudbreak Pharma's products are at different stages of pre-clinical and clinical development. The company generates revenue through the successful development, approval, and subsequent sale of these drugs. Its mission is to improve people's vision and quality of life through medicine, with a particular focus on creating the first therapeutic treatment for pterygia.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- Irvine, United States
- Employees
- 16
- Open positions
- None listed
- Dealroom signal
- 47.4/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| IPOOther financing | Jul 2025 | $74M | $74M | Undisclosed | ↗ |
| SERIES COther financing | Jan 2022 | $130M | $520M | ShenZhen GTJA Investment Group · Yingke Capital · Shenzhen CDF Capital · CDH Investments | ↗ |
Growth signals
Latest recorded traffic for Cloudbreak Therapeutics is 4.1K monthly website visits, up 215.4% over the last three months. Cloudbreak Therapeutics's team grew 14.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
- HCHY Capital
BOC International- LCLumiere Capital
VCapital
V-Capital
China Grand Pharmaceutical and Healthcare Holdings
Series B and later5 investors entered at this stage
- SGShenZhen GTJA Investment Group
Yingke Capital
Shenzhen CDF Capital
CDH Investments
Dyee Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Cloudbreak Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cloudbreak Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.